asked the Secretary of State for Social Services (1) what progress is being made with the development of a new whooping cough vaccine;(2) when the decision was taken to postpone the trials of new whooping cough vaccines; on which vaccines there were to have been trials; for what reasons the trials were postponed; and if he will make a statement.
[pursuant to her reply, 13 March 1987, c. 327]: A sub-committee of the Medical Research Council's
| Table I | |||||||
| Percentage of total whole milk utilisation used for milk products by member state: 1979–85 | |||||||
| Member State | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 |
| Belgium | 72 | 72 | 72 | 83 | 75 | 73 | 73 |
| Denmark | 85 | 83 | 85 | 85 | 85 | 86 | 84 |
| Germany | 80 | 80 | 80 | 77 | 80 | 78 | 76 |
| France | 68 | 71 | 70 | 70 | 72 | 71 | 70 |
| Ireland | 75 | 74 | 73 | 75 | 77 | 79 | 79 |
| Italy | 62 | 61 | 62 | 63 | 62 | 61 | 61 |
| Luxembourg | 77 | 77 | 74 | 73 | 69 | 69 | 69 |
| Netherlands | 87 | 85 | 93 | 95 | 93 | 93 | 93 |
| United Kingdom | 50 | 51 | 52 | 50 | 51 | 49 | 49 |
| Greece | . . | . . | . . | . . | . . | . . | . . |
| . . not available. | |||||||
Source: EC dairy facts and figures.
Table II
| ||||||||||||||||
Percentage of each member state's production of butter and skimmed milk powder (SMP) sold into intervention: 1979–86
| ||||||||||||||||
1979
| 1980
| 1981
| 1982
| 1983
| 1984
| 1985
| 19861
| |||||||||
Member state
| Butter
| SMP
| Butter
| SMP
| Butter
| SMP
| Butter
| SMP
| Butter
| SMP
| Butter
| SMP
| Butter
| SMP
| Butter
| SMP
|
| Belgium | 29·7 | 6·2 | 3·7 | 10·0 | 0 | 8·1 | 3·8 | 19·4 | 24·7 | 44·8 | 17·5 | 33·1 | 14·6 | 17·5 | 26·4 | 49·4 |
| Denmark | 1·3 | 0·1 | 0 | 0 | 0 | 17·3 | 2·3 | 24·9 | 8·1 | 62·7 | 0·6 | 0 | 10·8 | 16·7 | 6·0 | 53·8 |
| Germany | 34·1 | 21·3 | 19·1 | 12·1 | 0·8 | 23·5 | 11·0 | 30·4 | 32·7 | 44·2 | 32·9 | 35·9 | 27·1 | 28·8 | 31·8 | 43·0 |
| France | 6·0 | 0 | 2·0 | 1·3 | 1·3 | 3·7 | 4·9 | 3·9 | 21·7 | 10·6 | 16·7 | 3·0 | 13·4 | 4·2 | 20·8 | 8·1 |
| Ireland | 0 | 6·1 | 2·3 | 0 | 0 | 5·2 | 9·7 | 50·2 | 27·4 | 43·9 | 24·2 | 9·4 | 44·0 | 0 | 48·4 | 21·1 |
| Italy | 0 | 0 | 0 | 0 | 0 | 0 | 0·3 | 0 | 1·6 | 0 | 0·9 | 0 | 0·8 | 0 | 1·0 | 0 |
| Luxembourg | 37·5 | 31·8 | 22·5 | 0 | 1·4 | 24·8 | 0 | 37·4 | 3·7 | 36·7 | 12·0 | 35·1 | 13·1 | 0 | 9·4 | 50·8 |
committee on development of vaccines and immunological products is supervising the development of a new whooping cough vaccine and is co-ordinating arrangements for clinical trials of that and similar vaccines.
Requirements under section 31 of the Medicines Act 1968 on the safe conduct of clinical trials must be satisfied before such trials can be carried out in the United Kingdom. Information about particular applications cannot be given for reasons of commercial confidentiality.